View : 221 Download: 0

Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice

Title
Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice
Authors
Youn, Young JinYoo, Sang-YongLee, Jun-WonAhn, Sung GyunLee, Seung-HwanYoon, JunghanPark, Jae HyoungChoi, Woong GilCho, SungsooLim, Sang-WookJang, Yang SooKwon, Ki HwanLee, Nam HoDoh, Joon HyungKang, Woong CholJeon, Dong WoonLee, Bong-KiHeo, Jung HoHong, Bum-KeeChoi, Hyun-Hee
Ewha Authors
권기환
SCOPUS Author ID
권기환scopusscopus
Issue Date
2020
Journal Title
KOREAN CIRCULATION JOURNAL
ISSN
1738-5520JCR Link

1738-5555JCR Link
Citation
KOREAN CIRCULATION JOURNAL vol. 50, no. 4, pp. 317 - 327
Keywords
Drug-eluting stentsPercutaneous coronary interventionProspective studiesRegistries
Publisher
KOREAN SOC CARDIOLOGY
Indexed
SCIE; SCOPUS; KCI WOS
Document Type
Article
Abstract
Background and Objectives: Recently, Genoss drug-eluting stent (DES)(TM) stent comprising cobalt-chromium platform with an ultrathin strut thickness, sirolimus, and an abluminal biodegradable polymer was developed. Owing to the lack of substantial evidence for the safety and efficacy of this stent, we report 12-month results of the Genoss DES (TM) stent. Methods: We analyzed subjects who were eligible for a 12-month follow-up from the ongoing Genoss DES (TM) registry, which is a prospective, single-arm, observational, multicenter trial to investigate the clinical outcomes after the successful Genoss DES (TM) stent implantation among all-comers. The primary endpoint was a device-oriented composite outcome, defined as cardiac death, target vessel-related myocardial infarction, and target lesion revascularization at 12-month follow-up. Results: Among 622 subjects, the mean age of subjects was 66.5 +/- 10.4 years, 70.6% were males, 67.5% had hypertension, and 38.3% had diabetes. The implanted stent number, diameter, and length per patient were 1.5 +/- 0.8, 3.1 +/- 0.4 mm, and 36.0 +/- 23.3 mm, respectively. At 12-month clinical follow-up, the primary endpoint occurred only in 4 (0.6%) subjects. Conclusions: The novel Genoss DES (TM) stent exhibited excellent safety and efficacy in real-world practice.
Show the fulltext
DOI
10.4070/kcj.2019.0258
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE